SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cronstein BN, Naime D, Ostad E.. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 267582.
  • 2
    Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000; 43: 65663.
  • 3
    Montesinos MC, Cronstein B. Role of P1 receptors in inflammation. In: AbbracchioMP, WilliamsM, editors. Handbook of experimental pharmacology. Vol. 151/II: Purinergic and pyrmidinergic signalling II. Cardiovascular, respiratory, immune, metabolic and gastrointestinal tract function. Berlin: Springer-Verlag; 2001. p. 30321.
  • 4
    Matsuoka H, Ohi N, Mihara M, Suzuki H, Miyamoto K, Maruyama N, et al. Antirheumatic agents: novel methotrexate derivatives bearing a benzoxazine or benzothiazine moiety. J Med Chem 1997; 40: 10511.
  • 5
    Mihara M, Urakawa K, Takagi N, Moriya Y, Takeda Y. In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Immunopharmacology 1996; 35: 416.
  • 6
    Hiraoka M, Mihara M, Takeda Y, Miyasaka N. A novel non-polyglutamable anti-folate, MX-68, inhibits the induction of experimental autoimmune uveitis in rats. Exp Eye Res 1998; 67: 18.
  • 7
    Mihara M, Suzuki T, Kaneko E, Takagi N, Takeda Y. Immunosuppressive properties of MX-68, a novel unpolyglutamatable antifolate. Biol Pharm Bull 1997; 20: 10715.
  • 8
    Mihara M, Takagi N, Urakawa K, Moriya Y, Takeda Y. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice. Int Arch Allergy Immunol 1997; 113: 4549.
  • 9
    Urakawa K, Mihara M, Suzuki T, Kawamura A, Akamatsu K, Takeda Y, et al. Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects. Immunopharmacology 2000; 48: 13744.
  • 10
    Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192200.
  • 11
    Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000; 275: 442934.
  • 12
    Montesinos MC, Desai A, Chen J-F, Yee H, Jacobson M, Schwarz-schild M, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. Am J Pathol 2002; 160: 20009.
  • 13
    Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 91620.
  • 14
    Fairbanks LD, Ruckemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999; 342: 14352.
  • 15
    Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 3228.
  • 16
    Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 9971002.
  • 17
    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 918.
  • 18
    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 83341.
  • 19
    Dijkmans BA. Folate supplementation and methotrexate. Br J Rheumatol 1995; 34: 11724.
  • 20
    Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 115861.
  • 21
    Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36: 795803.
  • 22
    Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988; 15: 107880.
  • 23
    Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991; 88: 24415.
  • 24
    Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101: 295300.
  • 25
    Andersson SE, Johansson LH, Lexmuller K, Ekstrom GM. Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Eur J Pharm Sci 2000; 9: 33343.
  • 26
    Laghi Pasini F, Capecchi PL, Di Perri T. Adenosine plasma levels after low dose methotrexate administration [letter]. J Rheumatol 1997; 24: 24923.
  • 27
    Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999; 135: 8137.
  • 28
    Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis 1999; 5: 16773.
  • 29
    Silke C, Murphy MS, Buckley T, Busteed S, Molloy MG, Phelan M. The effects of caffeine ingestion on the efficacy of methotrexate [abstract]. Rheumatology (Oxford) 2001; 40 Suppl 1: 34.
  • 30
    Khakh BS, Kennedy C. Adenosine and ATP: progress in their receptors' structures and functions. Trends Pharmacol Sci 1998; 19: 3941.
  • 31
    Cronstein BN. Adenosine and its receptors during inflammation. In: SerhanCN, WardPA, editors. Molecular and cellular basis of inflammation. Totowa (NJ): Humana Press; 1998. p. 25974.
  • 32
    McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol 1996; 310: 20916.
  • 33
    Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157: 463440.
  • 34
    Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996; 156: 343542.
  • 35
    Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, et al. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998; 125: 37987.
  • 36
    Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, et al. Adenosine inhibits IL-12 and TNF-alpha production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000; 14: 206574.
  • 37
    Xaus J, Mirabet M, Lloberas J, Soler C, Lluis C, Franco R, et al. IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J Immunol 1999; 162: 360714.
  • 38
    Le Moine O, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, et al. Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996; 156: 440814.
  • 39
    Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells. J Immunol 2001; 167: 402632.
  • 40
    Salmon JE, Brogle N, Brownlie C, Edberg JC, Kimberly RP, Chen BX, et al. Human mononuclear phagocytes express adenosine A1 receptors: a novel mechanism for differential regulation of Fc gamma receptor function. J Immunol 1993; 151: 277585.
  • 41
    Sullivan GW, Linden J, Buster BL, Scheld WM. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J Infect Dis 1999; 180: 155060.
  • 42
    Matherne GP, Headrick JP, Coleman SD, Berne RM. Interstitial transudate purines in normoxic and hypoxic immature and mature rabbit hearts. Pediatr Res 1990; 28: 34853.
  • 43
    Schrader J. Adenosine: a homeostatic metabolite in cardiac energy metabolism. Circulation 1990; 81: 38991.
  • 44
    Deussen A, Schrader J. Cardiac adenosine production is linked to myocardial pO2. J Mol Cell Cardiol 1991; 23: 495504.
  • 45
    Borst MM, Schrader J. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ Res 1991; 68: 797806.
  • 46
    Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989; 256: C799806.
  • 47
    Kitakaze M, Hori M, Morioka T, Takashima S, Minamino T, Sato H, et al. Attenuation of ecto-5′-nucleotidase activity and adenosine release in activated human polymorphonuclear leukocytes. Circ Res 1993; 73: 52433.
  • 48
    Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, et al. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5′-nucleotidase. Circulation 1996; 93: 78191.
  • 49
    Node K, Kitakaze M, Minamino T, Tada M, Inoue M, Hori M, et al. Activation of ecto-5′-nucleotidase by protein kinase C and its role in ischaemic tolerance in the canine heart. Br J Pharmacol 1997; 120: 27381.
  • 50
    Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 116077.
  • 51
    Newby AC, Holmquist CA, Illingworth J, Pearson JD. The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J 1983; 214: 31723.
  • 52
    Cronstein BN, Naime D, Firestein G. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 1995; 38: 10405.
  • 53
    Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156: 193741.
  • 54
    Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A 1999; 96: 637781.
  • 55
    Hwang KK, Hall CS, Spielman WS, Sparks HV. FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur J Pharmacol 2001; 425: 8593.
  • 56
    Colli S, Tremoli E. Multiple effects of dipyridamole on neutrophils and mononuclear leukocytes: adenosine-dependent and adenosine-independent mechanisms. J Lab Clin Med 1991; 118: 13645.
  • 57
    Krauss SW, Ghirnikar RB, Diamond I, Gordon AS. Inhibition of adenosine uptake by ethanol is specific for one class of nucleoside transporters. Mol Pharmacol 1993; 44: 10216.
  • 58
    Diamond I, Gordon AS. The role of adenosine in mediating cellular and molecular responses to ethanol. EXS 1994; 71: 17583.